{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:11:51Z","timestamp":1791594711246,"version":"4.3.4"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI114780"],"award-info":[{"award-number":["R01-AI114780"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21-AI142198"],"award-info":[{"award-number":["R21-AI142198"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI104739"],"award-info":[{"award-number":["R01AI104739"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"crossref","award":["U54-NS115054"],"award-info":[{"award-number":["U54-NS115054"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myasthenia gravis (MG) is an autoantibody-mediated autoimmune disorder of the neuromuscular junction. A small subset of patients (&lt;10%) with MG, have autoantibodies targeting muscle-specific tyrosine kinase (MuSK). MuSK MG patients respond well to CD20-mediated B cell depletion therapy (BCDT); most achieve complete stable remission. However, relapse often occurs. To further understand the immunomechanisms underlying relapse, we studied autoantibody-producing B cells over the course of BCDT. We developed a fluorescently labeled antigen to enrich for MuSK-specific B cells, which was validated with a novel Nalm6 cell line engineered to express a human MuSK-specific B cell receptor. B cells (\u2245 2.6 million) from 12 different samples collected from nine MuSK MG patients were screened for MuSK specificity. We successfully isolated two MuSK-specific IgG4 subclass-expressing plasmablasts from two of these patients, who were experiencing a relapse after a BCDT-induced remission. Human recombinant MuSK mAbs were then generated to validate binding specificity and characterize their molecular properties. Both mAbs were strong MuSK binders, they recognized the Ig1-like domain of MuSK, and showed pathogenic capacity when tested in an acetylcholine receptor\u00a0(AChR) clustering assay. The presence of persistent clonal relatives of these MuSK-specific B cell clones was investigated through B cell receptor repertoire tracing of 63,977 unique clones derived from longitudinal samples collected from these two patients. Clonal variants were detected at multiple timepoints spanning more than five years and reemerged after BCDT-mediated remission, predating disease relapse by several months. These findings demonstrate that a reservoir of rare pathogenic MuSK autoantibody-expressing B cell clones survive BCDT and reemerge into circulation prior to manifestation of clinical relapse. Overall, this study provides both a mechanistic understanding of MuSK MG relapse and a valuable candidate biomarker for relapse prediction.<\/jats:p>","DOI":"10.1186\/s40478-022-01454-0","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T15:08:19Z","timestamp":1666969699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy"],"prefix":"10.1186","volume":"10","author":[{"given":"Miriam L.","family":"Fichtner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Hoehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Easton E.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mane-Damas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangwook","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee S.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey T.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Losen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Martinez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Kleinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7056-419X","authenticated-orcid":false,"given":"Kevin C.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"1454_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1352458517740641","volume":"25","author":"MA Agius","year":"2019","unstructured":"Agius MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K, Wesley J, Madani S, Barron G, Katz E et al (2019) Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Multiple Scler J 25:235\u2013245. https:\/\/doi.org\/10.1177\/1352458517740641","journal-title":"Multiple Scler J"},{"key":"1454_CR2","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1002\/art.22810","volume":"56","author":"JH Anolik","year":"2007","unstructured":"Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I (2007) Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56:3044\u20133056. https:\/\/doi.org\/10.1002\/art.22810","journal-title":"Arthritis Rheum"},{"key":"1454_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/cei.13024","volume":"190","author":"E Becerra","year":"2017","unstructured":"Becerra E, De La Torre I, Leandro MJ, Cambridge G (2017) B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets. Clin Exp Immunol 190:372\u2013383. https:\/\/doi.org\/10.1111\/cei.13024","journal-title":"Clin Exp Immunol"},{"key":"1454_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","volume":"82","author":"S Blum","year":"2011","unstructured":"Blum S, Gillis D, Brown H, Boyle R, Henderson R, Heyworth-Smith D, Hogan P, Kubler P, Lander C, Limberg N et al (2011) Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol, Neurosurg Psychiat 82:659\u2013663. https:\/\/doi.org\/10.1136\/jnnp.2010.220475","journal-title":"J Neurol, Neurosurg Psychiat"},{"key":"1454_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P, Papalexi E, Satija R (2018) Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nature Biotechnol 36:411\u2013420. https:\/\/doi.org\/10.1038\/nbt.4096","journal-title":"Nature Biotechnol"},{"key":"1454_CR6","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.4049\/jimmunol.1401478","volume":"193","author":"D Chen","year":"2014","unstructured":"Chen D, Blazek M, Ireland S, Ortega S, Kong X, Meeuwissen A, Stowe A, Carter L, Wang Y, Herbst R et al (2014) Single dose of Glycoengineered Anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms. J Immunol 193:4823\u20134832. https:\/\/doi.org\/10.4049\/jimmunol.1401478","journal-title":"J Immunol"},{"key":"1454_CR7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/acn3.564","volume":"5","author":"E Cort\u00e9s-Vicente","year":"2018","unstructured":"Cort\u00e9s-Vicente E, Rojas-Garcia R, D\u00edaz-Manera J, Querol L, Casasnovas C, Guerrero-Sola A, Mu\u00f1oz-Blanco JL, B\u00e1rcena-Llona JE, M\u00e1rquez-Infante C, Pardo J et al (2018) The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann Clin Trans Neurol 5:710\u2013716. https:\/\/doi.org\/10.1002\/acn3.564","journal-title":"Ann Clin Trans Neurol"},{"key":"1454_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R et al (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(19)31817-3","journal-title":"Lancet"},{"key":"1454_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc3961","author":"E Crickx","year":"2021","unstructured":"Crickx E, Chappert P, Sokal A, Weller S, Azzaoui I, Vandenberghe A, Bonnard G, Rossi G, Fadeev T, Storck S et al (2021) Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abc3961","journal-title":"Sci Transl Med"},{"key":"1454_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J Diaz-Manera","year":"2012","unstructured":"Diaz-Manera J, Martinez-Hernandez E, Querol L, Klooster R, Rojas-Garcia R, Suarez-Calvet X, Munoz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E et al (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78:189\u2013193. https:\/\/doi.org\/10.1212\/WNL.0b013e3182407982","journal-title":"Neurology"},{"key":"1454_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G et al (2016) Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353:179\u2013184. https:\/\/doi.org\/10.1126\/science.aaf6756","journal-title":"Science"},{"key":"1454_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12015-020-10092-9","volume":"17","author":"J Feng","year":"2021","unstructured":"Feng J, Xu H, Cinquina A, Wu Z, Chen Q, Zhang P, Wang X, Shan H, Xu L, Zhang Q et al (2021) Treatment of Aggressive T Cell Lymphoblastic Lymphoma\/leukemia Using Anti-CD5 CAR T Cells. Stem Cell Rev Rep 17:652\u2013661. https:\/\/doi.org\/10.1007\/s12015-020-10092-9","journal-title":"Stem Cell Rev Rep"},{"key":"1454_CR13","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Jiang R, Bourke A, Nowak RJ, O\u2019Connor KC (2020) Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 11:776. https:\/\/doi.org\/10.3389\/fimmu.2020.00776","journal-title":"Front Immunol"},{"key":"1454_CR14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200513","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Vieni C, Redler RL, Kolich L, Jiang R, Takata K, Stathopoulos P, Suarez PA, Nowak RJ, Burden SJ et al (2020) Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20200513","journal-title":"J Exp Med"},{"key":"1454_CR15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1417683112","author":"D Gadala-Maria","year":"2015","unstructured":"Gadala-Maria D, Yaari G, Uduman M, Kleinstein SH (2015) Automated analysis of high-throughput B-cell sequencing data reveals a high frequency of novel immunoglobulin V gene segment alleles. Proc Natl Acad Sci U S A: https:\/\/doi.org\/10.1073\/pnas.1417683112","journal-title":"Proc Natl Acad Sci U S A:"},{"key":"1454_CR16","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"1454_CR17","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1016\/j.ajpath.2016.05.025","volume":"186","author":"AM Gomez","year":"2016","unstructured":"Gomez AM, Stevens JA, Mane-Damas M, Molenaar P, Duimel H, Verheyen F, Cossins J, Beeson D, De Baets MH, Losen M et al (2016) Silencing of Dok-7 in adult rat muscle increases susceptibility to passive transfer myasthenia gravis. Am J Pathol 186:2559\u20132568. https:\/\/doi.org\/10.1016\/j.ajpath.2016.05.025","journal-title":"Am J Pathol"},{"key":"1454_CR18","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4049\/jimmunol.158.4.1919","volume":"158","author":"YF Graus","year":"1997","unstructured":"Graus YF, de Baets MH, Parren PW, Berrih-Aknin S, Wokke J, van Breda Vriesman PJ, Burton DR (1997) Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. J Immunol 158:1919\u20131929","journal-title":"J Immunol"},{"key":"1454_CR19","doi-asserted-by":"crossref","unstructured":"Guidicelli VCD, Bodmer J, M\u00c5ller W, Busin C, Mash S, Bontrop R, Marc L, Malik A, Lefranc MP (1997) IMGT, The International ImMunoGeneTics database. 25: 206-211","DOI":"10.1093\/nar\/25.1.206"},{"key":"1454_CR20","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.4049\/jimmunol.1601850","volume":"198","author":"NT Gupta","year":"2017","unstructured":"Gupta NT, Adams KD, Briggs AW, Timberlake SC, Vigneault F, Kleinstein SH (2017) Hierarchical clustering can identify B cell clones with high confidence in Ig repertoire sequencing data. J Immunol 198:2489\u20132499. https:\/\/doi.org\/10.4049\/jimmunol.1601850","journal-title":"J Immunol"},{"key":"1454_CR21","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1093\/bioinformatics\/btv359","volume":"31","author":"NT Gupta","year":"2015","unstructured":"Gupta NT, Vander Heiden JA, Uduman M, Gadala-Maria D, Yaari G, Kleinstein SH (2015) Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics 31:3356\u20133358. https:\/\/doi.org\/10.1093\/bioinformatics\/btv359","journal-title":"Bioinformatics"},{"key":"1454_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Sanders DB, Evoli A (2011) Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 44:36\u201340. https:\/\/doi.org\/10.1002\/mus.22006","journal-title":"Muscle Nerve"},{"key":"1454_CR23","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M et al (2021) Integrated analysis of multimodal single-cell data. Cell 184:3573-3587.e3529. https:\/\/doi.org\/10.1016\/j.cell.2021.04.048","journal-title":"Cell"},{"key":"1454_CR24","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/wnl.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, Zvartau-Hind M, Bril V (2018) Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology 90:e1425\u2013e1434. https:\/\/doi.org\/10.1212\/wnl.0000000000005323","journal-title":"Neurology"},{"key":"1454_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi O, Hamuro J, Motomura M, Yamanashi Y (2011) Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 69:418\u2013422. https:\/\/doi.org\/10.1002\/ana.22312","journal-title":"Ann Neurol"},{"key":"1454_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365\u2013368","journal-title":"Nat Med"},{"key":"1454_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1009885","volume":"18","author":"KB Hoehn","year":"2022","unstructured":"Hoehn KB, Pybus OG, Kleinstein SH (2022) Phylogenetic analysis of migration, differentiation, and class switching in B cells. PLoS Comput Biol 18:e1009885. https:\/\/doi.org\/10.1371\/journal.pcbi.1009885","journal-title":"PLoS Comput Biol"},{"key":"1454_CR28","doi-asserted-by":"publisher","first-page":"22664","DOI":"10.1073\/pnas.1906020116","volume":"116","author":"KB Hoehn","year":"2019","unstructured":"Hoehn KB, Vander Heiden JA, Zhou JQ, Lunter G, Pybus OG, Kleinstein SH (2019) Repertoire-wide phylogenetic models of B cell molecular evolution reveal evolutionary signatures of aging and vaccination. Proc Natl Acad Sci U S A 116:22664\u201322672. https:\/\/doi.org\/10.1073\/pnas.1906020116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1454_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000547","volume":"6","author":"MG Huijbers","year":"2019","unstructured":"Huijbers MG, Vergoossen DL, Fillie-Grijpma YE, van Es IE, Koning MT, Slot LM, Veelken H, Plomp JJ, van der Maarel SM, Verschuuren JJ (2019) MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity. Neurol Neuroimmunol Neuroinflamm 6:e547. https:\/\/doi.org\/10.1212\/NXI.0000000000000547","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1454_CR30","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","volume":"110","author":"MG Huijbers","year":"2013","unstructured":"Huijbers MG, Zhang W, Klooster R, Niks EH, Friese MB, Straasheijm KR, Thijssen PE, Vrolijk H, Plomp JJ, Vogels P et al (2013) MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A 110:20783\u201320788. https:\/\/doi.org\/10.1073\/pnas.1313944110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1454_CR31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136471","author":"R Jiang","year":"2020","unstructured":"Jiang R, Fichtner ML, Hoehn KB, Pham MC, Stathopoulos P, Nowak RJ, Kleinstein SH, O\u2019Connor KC (2020) Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses. JCI Insight: https:\/\/doi.org\/10.1172\/jci.insight.136471","journal-title":"JCI Insight:"},{"key":"1454_CR32","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/s0140-6736(17)30070-3","volume":"389","author":"P Joly","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C et al (2017) First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet (London, England) 389:2031\u20132040. https:\/\/doi.org\/10.1016\/s0140-6736(17)30070-3","journal-title":"Lancet (London, England)"},{"key":"1454_CR33","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","volume":"84","author":"B Keung","year":"2013","unstructured":"Keung B, Robeson KR, DiCapua DB, Rosen JB, O\u2019Connor KC, Goldstein JM, Nowak RJ (2013) Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J Neurol Neurosurg Psychiatry 84:1407\u20131409. https:\/\/doi.org\/10.1136\/jnnp-2012-303664","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1454_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.05.010","volume":"199","author":"JY Kim","year":"2008","unstructured":"Kim JY, Yang Y, Moon JS, Lee EY, So SH, Lee HS, Park KD, Choi YC (2008) Serum BAFF expression in patients with myasthenia gravis. J Neuroimmunol 199:151\u2013154. https:\/\/doi.org\/10.1016\/j.jneuroim.2008.05.010","journal-title":"J Neuroimmunol"},{"key":"1454_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","volume":"77","author":"I Koneczny","year":"2017","unstructured":"Koneczny I, Stevens JA, De Rosa A, Huda S, Huijbers MG, Saxena A, Maestri M, Lazaridis K, Zisimopoulou P, Tzartos S et al (2017) IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. J Autoimmun 77:104\u2013115. https:\/\/doi.org\/10.1016\/j.jaut.2016.11.005","journal-title":"J Autoimmun"},{"key":"1454_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JCW (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis & Rheumatism 54:613\u2013620. https:\/\/doi.org\/10.1002\/art.21617","journal-title":"Arthritis & Rheumatism"},{"key":"1454_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/acn3.311","volume":"3","author":"JY Lee","year":"2016","unstructured":"Lee JY, Stathopoulos P, Gupta S, Bannock JM, Barohn RJ, Cotzomi E, Dimachkie MM, Jacobson L, Lee CS, Morbach H et al (2016) Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Ann Clin Transl Neurol 3:443\u2013454. https:\/\/doi.org\/10.1002\/acn3.311","journal-title":"Ann Clin Transl Neurol"},{"key":"1454_CR38","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","volume":"131","author":"L Lee","year":"2018","unstructured":"Lee L, Draper B, Chaplin N, Philip B, Chin M, Galas-Filipowicz D, Onuoha S, Thomas S, Baldan V, Bughda R et al (2018) An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood 131:746\u2013758. https:\/\/doi.org\/10.1182\/blood-2017-05-781351","journal-title":"Blood"},{"key":"1454_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1749-6632.2012.06842.x","volume":"1274","author":"RP Lisak","year":"2012","unstructured":"Lisak RP, Ragheb S (2012) The role of B cell-activating factor in autoimmune myasthenia gravis. Ann New York Acad Sci 1274:60\u201367. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06842.x","journal-title":"Ann New York Acad Sci"},{"key":"1454_CR40","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2008-09-177139","volume":"113","author":"XM Luo","year":"2009","unstructured":"Luo XM, Maarschalk E, O\u2019Connell RM, Wang P, Yang L, Baltimore D (2009) Engineering human hematopoietic stem\/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 113:1422\u20131431. https:\/\/doi.org\/10.1182\/blood-2008-09-177139","journal-title":"Blood"},{"key":"1454_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","volume":"9","author":"F Mackay","year":"2009","unstructured":"Mackay F, Schneider P (2009) Cracking the BAFF code. Nature Rev Immunol 9:491\u2013502. https:\/\/doi.org\/10.1038\/nri2572","journal-title":"Nature Rev Immunol"},{"key":"1454_CR42","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1182\/blood-2007-11-123844","volume":"111","author":"M Mamani-Matsuda","year":"2008","unstructured":"Mamani-Matsuda M, Cosma A, Weller S, Faili A, Staib C, Gar\u00e7on L, Hermine O, Beyne-Rauzy O, Fieschi C, Pers J-O et al (2008) The human spleen is a major reservoir for long-lived vaccinia virus\u2013specific memory B cells. Blood 111:4653\u20134659. https:\/\/doi.org\/10.1182\/blood-2007-11-123844","journal-title":"Blood"},{"key":"1454_CR43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100225","author":"C Mandel-Brehm","year":"2021","unstructured":"Mandel-Brehm C, Fichtner ML, Jiang R, Winton VJ, Vazquez SE, Pham MC, Hoehn KB, Kelleher NL, Nowak RJ, Kleinstein SH et al (2021) Elevated N-linked glycosylation of IgG V regions in myasthenia gravis disease subtypes. J Immunol. https:\/\/doi.org\/10.4049\/jimmunol.2100225","journal-title":"J Immunol"},{"key":"1454_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00613","author":"M Marino","year":"2020","unstructured":"Marino M, Basile U, Spagni G, Napodano C, Iorio R, Gulli F, Todi L, Provenzano C, Bartoccioni E, Evoli aA, (2020) Long lasting rituximab-induced reduction of specific - but not of total- IgG4 in MuSK-positive myasthenia gravis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.00613","journal-title":"Front Immunol"},{"key":"1454_CR45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/imr.12821","volume":"292","author":"E Meffre","year":"2019","unstructured":"Meffre E, O\u2019Connor KC (2019) Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev 292:90\u2013101. https:\/\/doi.org\/10.1111\/imr.12821","journal-title":"Immunol Rev"},{"key":"1454_CR46","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/genetics\/148.3.929","volume":"148","author":"R Nielsen","year":"1998","unstructured":"Nielsen R, Yang Z (1998) Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics 148:929\u2013936. https:\/\/doi.org\/10.1093\/genetics\/148.3.929","journal-title":"Genetics"},{"key":"1454_CR47","doi-asserted-by":"publisher","unstructured":"Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S et al (2021) Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: The BeatMG Study. Neurology 98: 376-389 doi https:\/\/doi.org\/10.1212\/wnl.0000000000013121","DOI":"10.1212\/wnl.0000000000013121"},{"key":"1454_CR48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/1756285611411503","volume":"4","author":"RJ Nowak","year":"2011","unstructured":"Nowak RJ, DiCapua DB, Zebardast N, Goldstein JM (2011) Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Therapeutic Adv Neurol Dis 4:259\u2013266. https:\/\/doi.org\/10.1177\/1756285611411503","journal-title":"Therapeutic Adv Neurol Dis"},{"key":"1454_CR49","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ana.21641","volume":"65","author":"GP Owens","year":"2009","unstructured":"Owens GP, Bennett JL, Lassmann H, O\u2019Connor KC, Ritchie AM, Shearer A, Lam C, Yu X, Birlea M, Dupree C et al (2009) Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 65:639\u2013649. https:\/\/doi.org\/10.1002\/ana.21641","journal-title":"Ann Neurol"},{"key":"1454_CR50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","volume":"259","author":"A Pevzner","year":"2012","unstructured":"Pevzner A, Schoser B, Peters K, Cosma NC, Karakatsani A, Schalke B, Melms A, Kroger S (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 259:427\u2013435. https:\/\/doi.org\/10.1007\/s00415-011-6194-7","journal-title":"J Neurol"},{"key":"1454_CR51","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.4049\/jimmunol.1501843","volume":"196","author":"TD Quach","year":"2016","unstructured":"Quach TD, Rodriguez-Zhurbenko N, Hopkins TJ, Guo X, Hernandez AM, Li W, Rothstein TL (2016) Distinctions among circulating antibody-secreting cell populations, including B-1 cells, in human adult peripheral blood. J Immunol 196:1060\u20131069. https:\/\/doi.org\/10.4049\/jimmunol.1501843","journal-title":"J Immunol"},{"key":"1454_CR52","doi-asserted-by":"publisher","unstructured":"Querol L, Rojas-Garc\u00eda R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, Sedano MJ, Ser\u00f3-Ballesteros L, Carvajal A, Ortiz N et al (2015) Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurology(R) neuroimmunology & neuroinflammation https:\/\/doi.org\/10.1212\/nxi.0000000000000149","DOI":"10.1212\/nxi.0000000000000149"},{"key":"1454_CR53","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A et al (2019) Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. The New England journal of medicine 380:1726\u20131737. https:\/\/doi.org\/10.1056\/NEJMoa1817226","journal-title":"The New England journal of medicine"},{"key":"1454_CR54","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","volume":"58","author":"TH Ramwadhdoebe","year":"2019","unstructured":"Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, Bruijnen STG, Safy M, Berger FH, Semmelink JF, van der Laken CJ, Gerlag DM, Thurlings RM et al (2019) Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology 58:1075\u20131085. https:\/\/doi.org\/10.1093\/rheumatology\/key428","journal-title":"Rheumatology"},{"key":"1454_CR55","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4190","author":"KR Robeson","year":"2016","unstructured":"Robeson KR, Kumar A, Keung B, DiCapua DB, Grodinsky E, Patwa HS, Stathopoulos PA, Goldstein JM, O\u2019Connor KC, Nowak RJ (2016) Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis. JAMA Neurol: https:\/\/doi.org\/10.1001\/jamaneurol.2016.4190","journal-title":"JAMA Neurol:"},{"key":"1454_CR56","first-page":"82","volume":"67","author":"A Rodgaard","year":"1987","unstructured":"Rodgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S (1987) Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol 67:82\u201388","journal-title":"Clin Exp Immunol"},{"key":"1454_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","volume":"36","author":"E Samy","year":"2017","unstructured":"Samy E, Wax S, Huard B, Hess H, Schneider P (2017) Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol 36:3\u201319. https:\/\/doi.org\/10.1080\/08830185.2016.1276903","journal-title":"Int Rev Immunol"},{"key":"1454_CR58","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1182\/blood-2010-10-307819","volume":"117","author":"S Sarantopoulos","year":"2011","unstructured":"Sarantopoulos S, Stevenson KE, Kim HT, Washel WS, Bhuiya NS, Cutler CS, Alyea EP, Ho VT, Soiffer RJ, Antin JH et al (2011) Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood 117:2275\u20132283. https:\/\/doi.org\/10.1182\/blood-2010-10-307819","journal-title":"Blood"},{"key":"1454_CR59","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1212\/WNL.31.8.935","volume":"31","author":"GK Scadding","year":"1981","unstructured":"Scadding GK, Vincent A, Newsom-Davis J, Henry K (1981) Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 31:935\u2013943","journal-title":"Neurology"},{"key":"1454_CR60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","volume":"18","author":"E Schiopu","year":"2016","unstructured":"Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K et al (2016) Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Therapy 18:131. https:\/\/doi.org\/10.1186\/s13075-016-1021-2","journal-title":"Arthritis Res Therapy"},{"key":"1454_CR61","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1136\/ard.2006.065656","volume":"66","author":"J Sellam","year":"2007","unstructured":"Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, Lacabaratz C, Gestermann N, Proust A, Lambotte O, Mariette X (2007) Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sj\u00f6gren\u2019s syndrome and systemic lupus erythematosus. Ann Rheumat Dis 66:790\u2013797. https:\/\/doi.org\/10.1136\/ard.2006.065656","journal-title":"Ann Rheumat Dis"},{"key":"1454_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aav6778","author":"J Sng","year":"2019","unstructured":"Sng J, Ayoglu B, Chen JW, Schickel J-N, Ferre EMN, Glauzy S, Romberg N, Hoenig M, Cunningham-Rundles C, Utz PJ et al (2019) AIRE expression controls the peripheral selection of autoreactive B cells. Sci Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aav6778","journal-title":"Sci Immunol"},{"key":"1454_CR63","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/nyas.13535","volume":"1412","author":"P Stathopoulos","year":"2018","unstructured":"Stathopoulos P, Kumar A, Heiden JAV, Pascual-Goni E, Nowak RJ, O\u2019Connor KC (2018) Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis. Ann N Y Acad Sci 1412:154\u2013165. https:\/\/doi.org\/10.1111\/nyas.13535","journal-title":"Ann N Y Acad Sci"},{"key":"1454_CR64","doi-asserted-by":"publisher","first-page":"e94263","DOI":"10.1172\/jci.insight.94263","volume":"2","author":"P Stathopoulos","year":"2017","unstructured":"Stathopoulos P, Kumar A, Nowak RJ, O\u2019Connor KC (2017) Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI Insight 2:e94263\u2013e94275. https:\/\/doi.org\/10.1172\/jci.insight.94263","journal-title":"JCI Insight"},{"key":"1454_CR65","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/BOR.0b013e328344c15e","volume":"23","author":"W Stohl","year":"2011","unstructured":"Stohl W, Scholz JL, Cancro MP (2011) Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol 23:305\u2013310. https:\/\/doi.org\/10.1097\/BOR.0b013e328344c15e","journal-title":"Curr Opin Rheumatol"},{"key":"1454_CR66","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.4049\/jimmunol.1502193","volume":"197","author":"K-Y Su","year":"2016","unstructured":"Su K-Y, Watanabe A, Yeh C-H, Kelsoe G, Kuraoka M (2016) Efficient culture of human naive and memory B cells for use as APCs. J Immunol 197:4163\u20134176. https:\/\/doi.org\/10.4049\/jimmunol.1502193","journal-title":"J Immunol"},{"key":"1454_CR67","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127167","author":"K Takata","year":"2019","unstructured":"Takata K, Stathopoulos P, Cao M, Mane-Damas M, Fichtner ML, Benotti ES, Jacobson L, Waters P, Irani SR, Martinez-Martinez P et al (2019) Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.127167","journal-title":"JCI Insight"},{"key":"1454_CR68","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mus.26609","volume":"60","author":"JD Triplett","year":"2019","unstructured":"Triplett JD, Hardy TA, Riminton DS, Chu SYK, Reddel SW (2019) Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: a marker of relapse? Muscle & nerve 60:307\u2013311. https:\/\/doi.org\/10.1002\/mus.26609","journal-title":"Muscle & nerve"},{"key":"1454_CR69","doi-asserted-by":"publisher","DOI":"10.3791\/52220","author":"N Tse","year":"2014","unstructured":"Tse N, Morsch M, Ghazanfari N, Cole L, Visvanathan A, Leamey C, Phillips WD (2014) The neuromuscular junction: measuring synapse size, fragmentation and changes in synaptic protein density using confocal fluorescence microscopy. J Vis Exp: https:\/\/doi.org\/10.3791\/52220","journal-title":"J Vis Exp:"},{"key":"1454_CR70","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","volume":"596","author":"JS Turner","year":"2021","unstructured":"Turner JS, O\u2019Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, Lei T, Thapa M, Chen RE, Case JB et al (2021) SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596:109\u2013113. https:\/\/doi.org\/10.1038\/s41586-021-03738-2","journal-title":"Nature"},{"key":"1454_CR71","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1093\/bioinformatics\/btu138","volume":"30","author":"JA Vander Heiden","year":"2014","unstructured":"Vander Heiden JA, Yaari G, Uduman M, Stern JN, O\u2019Connor KC, Hafler DA, Vigneault F, Kleinstein SH (2014) pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires. Bioinformatics 30:1930\u20131932. https:\/\/doi.org\/10.1093\/bioinformatics\/btu138","journal-title":"Bioinformatics"},{"key":"1454_CR72","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nprot.2017.126","volume":"13","author":"R Vazquez-Lombardi","year":"2018","unstructured":"Vazquez-Lombardi R, Nevoltris D, Luthra A, Schofield P, Zimmermann C, Christ D (2018) Transient expression of human antibodies in mammalian cells. Nature Protocols 13:99\u2013117. https:\/\/doi.org\/10.1038\/nprot.2017.126","journal-title":"Nature Protocols"},{"key":"1454_CR73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020635118","author":"DLE Vergoossen","year":"2021","unstructured":"Vergoossen DLE, Plomp JJ, Gstottner C, Fillie-Grijpma YE, Augustinus R, Verpalen R, Wuhrer M, Parren P, Dominguez-Vega E, van der Maarel SM et al (2021) Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2020635118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1454_CR74","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","volume":"2","author":"A Vincent","year":"2002","unstructured":"Vincent A (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2:797\u2013804","journal-title":"Nat Rev Immunol"},{"key":"1454_CR75","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1126\/science.10869071086907[pii]","volume":"301","author":"H Wardemann","year":"2003","unstructured":"Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC (2003) Predominant autoantibody production by early human B cell precursors. Science 301:1374\u20131377. https:\/\/doi.org\/10.1126\/science.10869071086907[pii]","journal-title":"Science"},{"key":"1454_CR76","doi-asserted-by":"crossref","unstructured":"Wickham H (2016) ggplot2: Elegant Graphics for Data Analysis Springer-Verlag New York, City","DOI":"10.1007\/978-3-319-24277-4"},{"key":"1454_CR77","first-page":"97","volume":"58","author":"HN Willcox","year":"1984","unstructured":"Willcox HN, Newsom-Davis J, Calder LR (1984) Cell types required for anti-acetylcholine receptor antibody synthesis by cultured thymocytes and blood lymphocytes in myasthenia gravis. Clin Exp Immunol 58:97\u2013106","journal-title":"Clin Exp Immunol"},{"key":"1454_CR78","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nature06890","volume":"453","author":"J Wrammert","year":"2008","unstructured":"Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C et al (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667\u2013671. https:\/\/doi.org\/10.1038\/nature06890","journal-title":"Nature"},{"key":"1454_CR79","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fimmu.2013.00358","volume":"4","author":"G Yaari","year":"2013","unstructured":"Yaari G, Vander Heiden JA, Uduman M, Gadala-Maria D, Gupta N, Stern JN, O\u2019Connor KC, Hafler DA, Laserson U, Vigneault F et al (2013) Models of somatic hypermutation targeting and substitution based on synonymous mutations from high-throughput immunoglobulin sequencing data. Front Immunol 4:358. https:\/\/doi.org\/10.3389\/fimmu.2013.00358","journal-title":"Front Immunol"},{"key":"1454_CR80","doi-asserted-by":"publisher","first-page":"W34","DOI":"10.1093\/nar\/gkt382","volume":"41","author":"J Ye","year":"2013","unstructured":"Ye J, Ma N, Madden TL, Ostell JM (2013) IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res 41:W34-40. https:\/\/doi.org\/10.1093\/nar\/gkt382","journal-title":"Nucleic Acids Res"},{"key":"1454_CR81","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","volume":"57","author":"JS Yi","year":"2018","unstructured":"Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O\u2019Connor KC (2018) B cells in the pathophysiology of myasthenia gravis. Muscle Nerve 57:172\u2013184. https:\/\/doi.org\/10.1002\/mus.25973","journal-title":"Muscle Nerve"},{"key":"1454_CR82","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1093\/molbev\/msy194","volume":"35","author":"G Yu","year":"2018","unstructured":"Yu G, Lam TT, Zhu H, Guan Y (2018) Two methods for mapping and visualizing associated data on phylogeny using ggtree. Mol Biol Evol 35:3041\u20133043. https:\/\/doi.org\/10.1093\/molbev\/msy194","journal-title":"Mol Biol Evol"},{"key":"1454_CR83","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000012463","author":"Z Yu","year":"2021","unstructured":"Yu Z, Zhang M, Jing H, Chen P, Cao R, Pan J, Luo B, Yu Y, Quarles BM, Xiong W et al (2021) Characterization of LRP4\/Agrin antibodies from a patient with myasthenia gravis. Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000012463","journal-title":"Neurology"},{"key":"1454_CR84","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1084\/jem.20042251","volume":"201","author":"S Yurasov","year":"2005","unstructured":"Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201:703\u2013711. https:\/\/doi.org\/10.1084\/jem.20042251","journal-title":"J Exp Med"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-022-01454-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-022-01454-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-022-01454-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T08:28:51Z","timestamp":1678436931000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-022-01454-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1186\/s40478-022-01454-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.07.21.22277677","asserted-by":"object"}]},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"29 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KCO has received research support from Alexion, now part of AstraZeneca, and Viela Bio, now part of Horizon Therapeutics, and Cabaletta Bio. KCO is a consultant and equity shareholder of Cabaletta Bio. During the last two years, KCO has served as consultant\/advisor for Alexion Pharmaceuticals, now part of AstraZeneca, and for Roche, and he has received speaking fees from Alexion, Roche, Genentech, Viela Bio, now part of Horizon Therapeutics, and UCB. MLF received a SPIN award from Grifols outside the submitted work and is a member of the Alexion-Akademie. KBH receives consulting fees from Prellis Biologics. SHK receives consulting fees from Peraton. ASP has received equity, research support, patent licensing and other payments from Cabaletta Bio; patent licensing payments from Novartis; and consultant fees from Janssen. SO has received patent licensing payments from Cabaletta Bio. The research of PMM and MMD at the School of Mental Health and Neuroscience, Faculty of Health, Medicine and Life Sciences was financially supported by Apellis, Argenx, Genmab, Neurotune and Takeda. PMM is a co-inventor of the following patent: Use of effector-function-deficient antibodies for treatment of auto-immune diseases (Patent number: 9181344). These competing interests played no role in the research design, reference collection, decision to publish, or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}